Gene therapy, biotechnology research, and rare disease treatment by Taysha Gene Therapies
Taysha Gene Therapies to share TSHA-102 gene therapy advancements at CNSAM event
Taysha Gene Therapies announced plans to share updates on its TSHA-102 gene therapy program, which is currently in clinical evaluation, at the Child Neurology Society Annual Meeting (CNSAM). The ...
TSHA-102 clinical trial results featured by Taysha Gene Therapies at Child Neurology Society Annual Meeting
Taysha Gene Therapies announced it will present multiple encore presentations supporting its TSHA-102 clinical program for Rett syndrome at the 55th Annual Meeting of the Child Neurology Society. ...
Taysha Gene Therapies, Inc. launches webinar to advance patient-centered Rett syndrome trials
Taysha Gene Therapies, Inc. is promoting a webinar hosted by the Child Neurology Society featuring Dr. Arthur Partikian, a leading expert in Rett syndrome. The session is set to explore how ...
TSHA-102 program reaches milestone as Taysha Gene Therapies Inc. finalizes REVEAL and ASPIRE dosing
Taysha Gene Therapies Inc. delivered its second quarter 2026 earnings report and announced a major development in its TSHA-102 gene therapy program. The company confirmed that dosing has been ...
Taysha Gene Therapies stock jumps 6.74% as TayshaGTx announces upcoming earnings update
Taysha Gene Therapies will announce its second quarter 2026 earnings and provide a corporate update next week. At the same time, Taysha Gene Therapies stock is up 6.7% on the day at $6.17.The ...
Taysha Gene Therapies, Inc. prepares for Q2 2026 earnings release and company update
Taysha Gene Therapies, Inc. will disclose its financial results for the second quarter of 2026 and provide a corporate update next week. The company has invited stakeholders to access additional ...
Taysha Gene Therapies stock trades down to $5.86 as company expands Catalent partnership
Taysha Gene Therapies announced it has expanded its partnership with Catalent through a commercial supply agreement for TSHA-102.TSHA-102 is an investigational gene therapy currently in clinical ...
Catalent to supply TSHA-102 under new commercial agreement with Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. has broadened its collaboration with Catalent by signing a commercial supply agreement for TSHA-102, the company’s investigational gene therapy currently in clinical ...
Taysha Gene Therapies, Inc. to present TSHA-102 Rett syndrome clinical program at scientific meeting
Taysha Gene Therapies, Inc. plans to deliver presentations on its TSHA-102 gene therapy program at the 2026 International Rett Syndrome Foundation Scientific Meeting, scheduled for June 29 to July ...
TSHA-102 construct design study advances Rett syndrome research at ASGCT 2026
Taysha Gene Therapies, Inc. released new preclinical data supporting the design of its TSHA-102 gene therapy for Rett syndrome at the upcoming ASGCT 2026 Annual Meeting. The company invited ...
Taysha Gene Therapies, Inc. engages Rettsyndrome community at Patient First event
Taysha Gene Therapies, Inc. participated in a Patient First event facilitated by Catalent and the International Rettsyndrome Foundation. The company expressed appreciation for the collaboration, ...
Earnings update from Taysha Gene Therapies expected next week
Taysha Gene Therapies, Inc. will announce its first quarter 2026 earnings and provide a corporate update next week. The company encouraged stakeholders to visit its website for further details ...
